Sun Pharma Adv.Res.Co.Ltd
Microcap 250
₹196.01
-0.46%
Delayed · cached 15 min
Fair value analysis
SPARC
Sun Pharma Adv.Res.Co.Ltd
₹196.91
Close used for this calculation
₹705.02Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
62/100
Quality radar
Consensus fair value
₹705.02
Below FV▲ +258.0% against the close used
Model range ₹214.47 – ₹1,708.60
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₹214.47Fair value₹705.02Bull₹1,708.60
FairClose
52-week traded range
52W low ₹108.7152W high ₹277.57
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
Sun Pharma Adv.Res.Co.Ltd closed at ₹196.91, 72.1% below the consensus fair value of ₹705.02 drawn from 6 valuation models.
Financial DNA score 62/100 — Good. P/E of 4.0x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₹897.02
+355.5%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₹214.47
+8.9%
√(22.5 × EPS × BVPS)
EPS=47.86, BVPS=42.71
P/E Fair Value
₹1,708.60
+767.7%
EPS × 35.7x (sector P/E)
EPS=47.86, Sector P/E=35.7x
EV/EBITDA
₹480.77
+144.2%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=16.09B
Reverse DCF
₹196.91
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: -10% | Historical: 0%
Margin of Safety
₹705.02
+258.0%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=940.03, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.